RPRX Royalty Pharma plc - Ordinary Shares - Class A
7,207
$28.49
$0.08
(0.28%)
| Watchers | 7,207 |
| 52-Wk Low | $25.92 |
| 52-Wk High | $35.70 |
| Market Cap | $12.81B |
| Volume | 1.86M |
| 52-Wk High | $35.70 |
| 52-Wk Low | $25.92 |
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty PharmaBusiness Wire • 4 days ago
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX). This milestone was triggered after the completion...
Share to Feed
Park Place Capital Corp lifted its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 52.2% during the fourth quarter, according to the company in its most recent disclosure with...
In trading on Wednesday, shares of Royalty Pharma plc (RPRX) crossed below their 200 day moving average of 29.00, changing hands as low as 28.68 per share. Royalty Pharma plc shares are...
Investors in Royalty Pharma plc (RPRX) saw new options become available today, for the January 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is...
Royalty Pharma (NASDAQ:RPRX - Get Free Report) was upgraded by StockNews.com from a "hold" rating to a "buy" rating in a research report issued on Saturday.
RPRX has been the topic of several other...
Wellington Management Group LLP lessened its holdings in Royalty Pharma plc (NASDAQ:RPRX Free Report) by 0.8% in the third quarter, according to its most recent 13F filing with the...
Royalty Pharma plc (NASDAQ:RPRX Get Free Report) has received a consensus rating of Buy from the four analysts that are currently covering the company, MarketBeat Ratings...
Vanguard Group Inc. increased its position in Royalty Pharma plc (NASDAQ:RPRX Free Report) by 1.5% in the 3rd quarter, according to the company in its most recent disclosure with the...
Key Insights Given the large stake in the stock by institutions, Royalty Pharma's stock price might be vulnerable to...
Royalty Pharma (NASDAQ:RPRX Get Free Report) was upgraded by research analysts at StockNews.com from a hold rating to a buy rating in a research report issued on...